RG
MRNA icon

Rathbones Group’s Moderna MRNA Stock Holding History

Rathbones Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$700K Buy
13,778
+195
+1% +$9.1K ﹤0.01% 414
2025
Q4 		$401K Sell
13,583
-2,620
-16% -$71.2K ﹤0.01% 484
2025
Q3 		$419K Buy
16,203
+1,589
+11% +$44.3K ﹤0.01% 463
2025
Q2 		$403K Buy
14,614
+5,019
+52% +$132K ﹤0.01% 457
2025
Q1 		$272K Buy
9,595
+365
+4% +$13K ﹤0.01% 478
2024
Q4 		$384K Sell
9,230
-1,744
-16% -$83.4K ﹤0.01% 445
2024
Q3 		$733K Sell
10,974
-1,754
-14% -$161K ﹤0.01% 360
2024
Q2 		$1.51M Buy
12,728
+100
+0.8% +$12.7K 0.01% 286
2024
Q1 		$1.35M Buy
12,628
+1,727
+16% +$174K 0.01% 292
2023
Q4 		$1.08M Buy
10,901
+1,371
+14% +$115K 0.01% 301
2023
Q3 		$984K Buy
9,530
+5,139
+117% +$573K 0.01% 313
2023
Q2 		$534K Buy
4,391
+130
+3% +$17.3K 0.01% 295
2023
Q1 		$654K Sell
4,261
-130
-3% -$21.4K 0.01% 279
2022
Q4 		$789K Buy
4,391
+629
+17% +$103K 0.01% 262
2022
Q3 		$445K Sell
3,762
-100
-3% -$15.2K 0.01% 296
2022
Q2 		$552K Buy
3,862
+459
+13% +$65.6K 0.01% 290
2022
Q1 		$586K Buy
+3,403
New +$573K 0.01% 289

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rathbones Group's MRNA Position: Q1 2026 in Review

Rathbones Group increased its Moderna (MRNA) stake by 1.4% in Q1 2026, buying an estimated $9.1K and bringing the position to 13,778 shares worth $700K. The position accounts for ﹤0.01% of the portfolio, ranked #414.

Rathbones Group first reported a position in MRNA in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.51M in Q2 2024. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Rathbones Group held 13,778 shares of Moderna worth $700K as of Q1 2026.
  • Rathbones Group bought 195 Moderna shares in Q1 2026, an estimated $9.1K.
  • Moderna made up ﹤0.01% of Rathbones Group's portfolio in Q1 2026, its #414 holding.
  • Rathbones Group first reported a position in Moderna in Q1 2022 and has held it in 17 quarters since.
  • Rathbones Group's Moderna position peaked at $1.51M in Q2 2024.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Rathbones Group's 13F filing for Q1 2026, filed 12 May 2026.